KLKonstantinos Lontos

Konstantinos Lontos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Konstantinos Lontos has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

    by Konstantinos Lontos, Rima M. Saliba, Rashmi Kanagal-Shamanna, Gonca Özcan, Jeremy Ramdial, George Chen, Tapan Kadia, Nicholas James Short, Naval G. Daver, Hagop Kantarjian, et al.

    Results after hematopoietic stem cell transplantation (HSCT) for TP53-mutated myeloid malignancies are disappointing. Several HSCT centers decline to perform HSCT for patients with TP53 mutation because of poor outcomes. In this study, we analyzed 240 patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who underwent HSCT. We aimed to identify the patients who benefit most from HSCT. The primary outcome was progression-free survival (PFS). Of the cohort, 52% had AML and the median age was 62 years. AML and MDS outcomes were similar. We identified several favorable prognostic factors for PFS, including absence of complex cytogenetics/5q deletion/7q deletion, a lower variant allele frequency (VAF), a monohit status, and use of a matched-related donor. Using classification and regression tree analysis, we identified VAF and cytogenetics as the 2 most important prognostic factors. Patients with TP53mut VAF ≥ 50% had a 2-year PFS of 3%, and patients with TP53mut VAF < 50% and complex/5q/7q cytogenetic abnormalities had 2-year PFS of 22%. Patients with TP53mut VAF < 50% and without complex/5q/7q cytogenetics had 2-year PFS of 60%. These data inform clinical practice and help patients decide whether to pursue HSCT.


  • Open Access

    Abstract A020: Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapy

    by Dayana Rivadeneira, Sanjana Thosar, Victoria Dean, William Gunn, Konstantinos Lontos, Marcel Bruchez, Patricia Opresko, Greg Delgoffe

    Background: Failure of adoptive cell therapies (ACTs) is associated with insufficient persistence within the patient, inability to infiltrate tumor sites, and cell-intrinsic loss of functionality. One of the key factors responsible for T cell dysfunction are metabolic barriers such as nutrient competition, low oxygen tension and damaging byproducts in the tumor microenvironment. This leads to a T cell metabolic deregulation affecting their ability to find and kill cancer cell targets properly and effectively. Therefore, elucidating the metabolic pressures experienced in the TME could provide new therapeutic targets to improve ACTs. Reactive Oxidative Species (ROS) accumulation in the TME have detrimental effects on T cell function and anti-tumor response, although the precise targets of ROS are unclear. There are accumulating data showing that mitochondrial ROS can have profound effects on the telomere status of cells. However, there is little evidence describing the role or oxidative stress on telomere health, or the importance of telomere function in immune cells. Our current study demonstrates that tumor infiltrating lymphocytes (TIL) accumulate DNA damage at telomeres, most prominently in terminally exhausted T cells. Furthermore, inducing ROS accumulation at telomeres alone drives T cell dysfunction. Importantly we discovered that alleviating ROS specifically at telomeres improves the response to adoptive cell therapies in a mouse tumor model. Methods: In this study we perform telomeric and centromeric FISH assays to analyze TIL for DNA damage accumulation. We used a chemo-optogenetic FAPS-TAPS to generate singlet oxygen and consequent 8-oxo-guanine lesions specifically at telomeres.1 We tethered the antioxidant protein GPX1 to TRF1, subunit of the Shelterin Complex at telomeres, to generate a telomere-guided ROS scavenger. Results: Telo-FISH analysis demonstrates an accumulation of telomeric DNA damage in TIL from B16 mouse tumors shown by the presence of 53BP1 and ƔH2AX at telomeres. Our data show that mitochondria and telomeric ROS cause the accumulation of DNA damage at telomeres, as well as the development of telomere fragility. These cells ultimately become dysfunctional showing a diminished capability for cytokine production. Importantly, localizing the ROS scavenger GPX1 directly to telomeres reduced telomere fragility and improved the function of therapeutic T cells in the B16 melanoma. Conclusions: Our data suggest that dysfunctional T cells in cancer are not classically senescent, bearing short telomeres, but rather harbor damaged telomeres due to exposure to oxidative stress. Telomeric damage is sufficient to drive a dysfunctional state in newly activated T cells. Protecting telomeres through expression of a telomere-targeted antioxidant protein may preserve T cell function in the tumor microenvironment and drive superior responses to adoptive cell therapies. Citation Format: Dayana Rivadeneira, Sanjana Thosar, Victoria Dean, William Gunn, Konstantinos Lontos, Marcel Bruchez, Patricia Opresko, Greg Delgoffe. Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr A020.

  • Open Access

    386 Sheltering telomeres from oxidative damage in therapeutic T cells protects against tumor-induced immune dysfunction

    by Dayana Rivadeneira, Sanjana Thosar, William Gunn, Victoria Dean, Konstantinos Lontos, Marcel Bruchez, Patricia Opresko, Greg Delgoffe

    Background Failure of adoptive cell therapies (ACTs) is associated with insufficient persistence within the patient, inability to infiltrate tumor sites, and cell-intrinsic loss of functionality. One of the key factors responsible for T cell dysfunction are metabolic barriers such as nutrient competition, low oxygen tension and damaging byproducts in the tumor microenvironment. This leads to a T cell metabolic deregulation affecting their ability to find and kill cancer cell targets effectively. Therefore, elucidating the metabolic pressures experienced in the TME could provide new therapeutic targets to improve ACTs. Reactive Oxidative Species (ROS) accumulation in the TME have detrimental effects on T cell function and anti-tumor response, although the precise targets of ROS are unclear. There are accumulating data showing that mitochondrial ROS can have profound effects on the telomere status of cells. However, there is little evidence describing the role or oxidative stress on telomere health, or the importance of telomere function in immune cells. Our current study demonstrates that tumor infiltrating lymphocytes (TIL) accumulate DNA damage at telomeres. Furthermore, inducing ROS accumulation at telomeres alone drives T cell dysfunction. Importantly we discovered that alleviating ROS specifically at telomeres improves the response to adoptive cell therapies in a mouse tumor model. Methods We perform telomeric and centromeric FISH assays to analyze TIL for DNA damage accumulation. We used a chemo-optogenetic FAPS-TAPS to generate oxidative lesions specifically at telomeres.1 We tethered the antioxidant protein GPX1 to the telomere shelterin TRF1 to generate a telomere-guided ROS scavenger. Results Telo-FISH analysis demonstrates an accumulation of telomeric DNA damage in TIL from B16 mouse tumors shown by the presence of 53BP1 and γH2AX at telomeres (figure 1A). Our data show that mitochondria and telomeric ROS cause the accumulation of DNA damage at telomeres, as well as the development of telomere fragility (figure 1B). These cells ultimately become dysfunctional showing a diminished capability for cytokine production. Importantly, localizing the ROS scavenger GPX1 directly to telomeres reduced telomere fragility and improved the function of therapeutic T cells in the B16 melanoma (figure 1C). Conclusions Our data suggest that dysfunctional T cells in cancer are not classically senescent, bearing short telomeres, but rather harbor damaged telomeres due to exposure to oxidative stress. Telomeric damage is sufficient to drive a dysfunctional state in newly activated T cells. Protecting telomeres through expression of a telomere-targeted antioxidant protein may preserve T cell function in the tumor microenvironment and drive superior responses to adoptive cell therapies. Reference Fouquerel E, Barnes RP, Uttam S, Watkins SC, Bruchez MP, Opresko PL. Targeted and persistent 8-oxoguanine base damage at telomeres promotes telomere loss and crisis. Mol Cell. 2019 Jul 11;75(1):117–130.e6. doi: 10.1016/j.molcel.2019.04.024. Epub 2019 May 14. PMID: 31101499; PMCID: PMC6625854. (A) Tumor infiltrating lymphocytes from B16 tumors and spleen sorted on PD1-Tim3 expression. FISH analysis of Telomere (Telo) and DNA damage response elements 53BP1 and γH2AX. (B) Activated T cells expression TRF1-FAP get oxidative damage induced at telomeres by chemoptogenetic method. T cells are arrested and perform metaphase spreads for telomere fragility analysis. (C) Therapeutic T cells co-expressing ROS scavenger GPX and TRF1 (telomere specific) transferred Into B16 tumor bearing mice. Control T cells express control plasmid PMIA.

  • Open Access

    An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment

    by Kristin DePeaux, Dayana B. Rivadeneira, Konstantinos Lontos, Victoria G. Dean, William G. Gunn, McLane J. Watson, Tianhong Yao, Drew Wilfahrt, Cynthia Hinck, Lukasz Wieteska, et al.

    While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments enhancing immune infiltration and preventing immunosuppression are of critical need. We previously generated αPD-1 resistant variants of the murine HNSCC model MEER. While entirely αPD-1 resistant, these tumors regress after single dose of oncolytic vaccinia virus (VV). We then generated a VV-resistant MEER line to dissect the immunologic features of sensitive and resistant tumors. While treatment of both tumor types induced immune infiltration and IFNγ, we found a defining feature of resistance was elevation of immunosuppressive cytokines like TGFβ, which blunted IFNγ signaling, especially in regulatory T cells. We engineered VV to express a genetically encoded TGFβRII inhibitor. Inhibitor-expressing VV produced regressions in resistant tumor models and showed impressive synergy with checkpoint blockade. Importantly, tumor-specific, viral delivery of TGFβ inhibition had no toxicities associated with systemic TGFβ/TGFβR inhibition. Our data suggest that aside from stimulating immune infiltration, oncolytic viruses are attractive means to deliver agents to limit immunosuppression in cancer.


  • Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.

    by Uday R. Popat, Konstantinos Lontos, Roland L. Bassett, Amin Majid Alousi, Gheath Alatrash, Qaiser Bashir, Chitra M. Hosing, Jin Seon Im, Partow Kebriaei, David Marin, et al.

  • Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy

    by Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, et al.

    Acute myeloid leukemia (AML) is a life-threatening disease that requires urgent treatment. The standard of care for initial treatment is induction chemotherapy, most commonly with a backbone includ...

  • Top Cited Papers

    Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity

    by Paolo D. A. Vignali, Kristin DePeaux, McLane J. Watson, Chenxian Ye, B. Rhodes Ford, Konstantinos Lontos, Nicole K. McGaa, Nicole E. Scharping, Ashley V. Menk, Simon C. Robson, et al.

    CD8+ T cells are critical for elimination of cancer cells. Factors within the tumor microenvironment (TME) can drive these cells to a hypofunctional state known as exhaustion. The most terminally exhausted T (tTex) cells are resistant to checkpoint blockade immunotherapy and might instead limit immunotherapeutic efficacy. Here we show that intratumoral CD8+ tTex cells possess transcriptional features of CD4+Foxp3+ regulatory T cells and are similarly capable of directly suppressing T cell proliferation ex vivo. tTex cell suppression requires CD39, which generates immunosuppressive adenosine. Restricted deletion of CD39 in endogenous CD8+ T cells resulted in slowed tumor progression, improved immunotherapy responsiveness and enhanced infiltration of transferred tumor-specific T cells. CD39 is induced on tTex cells by tumor hypoxia, thus mitigation of hypoxia limits tTex suppression. Together, these data suggest tTex cells are an important regulatory population in cancer and strategies to limit their generation, reprogram their immunosuppressive state or remove them from the TME might potentiate immunotherapy.


  • Open Access

    HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection

    by Rohtesh S. Mehta, Kai Cao, Rima M. Saliba, Gheath Al-Atrash, Amin M. Alousi, Konstantinos Lontos, Curtis Marcoux, Yudith Carmazzi, Gabriela Rondon, Qaiser Bashir, et al.


  • A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

    by Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, et al.

    Genomic profiling has allowed major advances in unraveling the complex molecular signature of acute myeloid leukemia (AML) and has informed us of the prognosis and survival of AML patients [1, 2]. ...

  • Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database

    by Aseel Alsouqi, Scott D. Rothenberger, Michael Boyiadzis, Konstantinos Lontos

    Summary: Acute myeloid leukaemia (AML) is conventionally thought of as a medical emergency. However, several studies on the association of time from diagnosis to treatment with survival did not have concordant results. Here we analyse 55 985 AML patients from the National Cancer Database, and we show that in patients less than 60 years old a five‐day delay in chemotherapy initiation leads to worse long‐term survival. The difference is small [hazard ratio (HR) 1.05, 95% confidence interval (CI) 1.01–1.09 in multivariate analysis] but statistically significant. This study raises the issue of power to detect small differences in retrospective studies.